GlassScriptPhysician profile
Ricardo Lerma
NPI 1043628712
$2,549.79
in general payments reported to CMS, 2019-2025
11 companies · $162 in 2025
The $162 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $700 · 2022: $607 · 2023: $300 · 2024: $781 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,242.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $506.65 | 2021-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $492.93 | 2021-2023 | Jardiance |
| Lilly USA, LLC | $454.35 | 2023-2024 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $342.28 | 2021-2024 | Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $170.42 | 2023-2024 | Xarelto |
| Glaxosmithkline, LLC. | $137.13 | 2022 | |
| Abbvie INC. | $125.01 | 2025 | |
| Viiv Healthcare Company | $125.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $119.26 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.39 | 2021 | |
| Astellas Pharma US INC | $15.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ricardo Lerma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.